As Covid-19 spending pushes the sector’s R&D bill ever higher, Lilly continues to plough the most back in as Sanofi applies the brakes.
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.
Yet another makeover raises fresh questions over Bellicum’s technology and sees its valuation haemorrhage some more.
Welcome to the calm before the Covid-19 storm.
The company’s chief financial officer leaves on the eve of its second-quarter earnings report; should investors be worried?
Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.
As a Covid-19 vaccine exclusivity and senior management storm engulfs Curevac, the German mRNA specialist insists it’s just conjecture and coincidence.